Document |
Document Title |
WO/2024/005658A1 |
The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of uterine body cancer. The invention also relates to an in vitro method for...
|
WO/2023/055580A9 |
Disclosed are benzylthiophene derivatives, pharmaceutical compositions comprising them, and methods of using them.
|
WO/2023/246631A1 |
Disclosed are a preparation method for a diazabicyclo peptidomimetic derivative and use thereof. The preparation method comprises: using an intramolecular nucleophilic substitution reaction in which sulfonamide is taken as a nucleophilic...
|
WO/2023/250339A2 |
The present disclosure provides therapeutic agents comprising VLA-4 (a4b1) and a4b?inhibiting agents defined herein. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA...
|
WO/2023/244963A2 |
The present disclosure provides compounds and methods to prepare an antibody conjugate with a fluorophore, as well as the methods of using these conjugates for cellular imaging. In one example, the conjugate may be coupled with a quenche...
|
WO/2023/242020A1 |
The invention provides a process for obtaining mixtures containing methionine and potassium hydrogencarbonate from aqueous solutions or suspensions containing titratable potassium in the form of potassium hydrogencarbonate and/or potassi...
|
WO/2023/245162A2 |
The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):
|
WO/2023/241632A1 |
Provided are a conjugate of an anti-CTLA-4 antibody activated by a tumor microenvironment and an application thereof. The conjugate of the present invention has the following structure: R1-R2-R3-L-R4-S-cys-R5, wherein R1, R2, R3, L, R4, ...
|
WO/2023/243720A1 |
Provided is a method for producing a silane-containing condensed ring dipeptide compound represented by formula (A). The method comprises: (i) a step for reacting a first amino acid represented by formula (R1) with a first silane compo...
|
WO/2023/245166A2 |
The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):
|
WO/2023/238961A1 |
The present invention provides a pH-responsive carrier for nucleic acid delivery to cells or tissues, comprising a combination of a cationic polymer having a side chain containing a primary amine and a block copolymer represented by the ...
|
WO/2023/236797A1 |
Disclosed in the present invention are a hangtaimycin derivative, a preparation method therefor, and the use thereof. The hangtaimycin derivative is prepared by performing fermentation in an SFMR culture medium by using Streptomyces spec...
|
WO/2023/235970A1 |
The present disclosure provides compounds with increased metabolic stability for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of th...
|
WO/2023/231988A1 |
A preparation method for a drug linker conjugate. Provided are a method for preparing the intermediate or the salt thereof, and the use of the intermediate or the salt thereof. The raw materials involved in the preparation method are eas...
|
WO/2023/231452A1 |
The present invention belongs to the technical field of radiopharmaceuticals and medical images. Disclosed in the present invention are a PSMA-targeting radioactive metal complex containing a nitro aromatic heterocyclic group and the pre...
|
WO/2023/231573A1 |
An isomer of a peptide derivative of formula (I), a mixture of stereoisomers thereof, or a salt thereof, or a composition thereof, and the use thereof. The isomer of the peptide derivative of formula (I) and the composition containing th...
|
WO/2023/235109A1 |
The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respirat...
|
WO/2023/234703A1 |
The present invention provides a novel peptide derivative containing a specific D-amino acid and a pharmaceutical composition for preventing, ameliorating, or treating ophthalmic diseases comprising same. The peptide derivative of the pr...
|
WO/2023/232573A1 |
202100366 Foreign Filing 13 Summary5 The present invention concerns the recovery of methionylmethionine from aqueous alkali ions containing media by intermediate formation of Bis(methionyl)-diketopiperazine.
|
WO/2023/232080A1 |
The present invention belongs to the field of biomedicine. Disclosed in the present invention are an anti-CLDN18.2 antibody, and an antibody-drug conjugate and use thereof. In some embodiments, the antibody-drug conjugate is a compound r...
|
WO/2023/226950A1 |
The present invention relates to a peptidomimetic STAT protein degrader, a composition and a use thereof. Disclosed are a structure represented by general formula (I), or a stereoisomer thereof, or a stereoisomer mixture thereof or a pha...
|
WO/2023/228095A1 |
The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-cadherin-6 (CDH6) antibody connected v...
|
WO/2023/227757A1 |
The invention provides protected ortho-quinone compounds comprising a group represented by: Formula (I) where -Ar- is optionally substituted phenylene, -X is selected from -NH2, -OH and -SH, and the protected forms of each, -W- is option...
|
WO/2023/220781A1 |
The present invention relates to β-peptides and hydrogels comprising the β-peptides. The hydrogels may further comprise a therapeutic cargo encapsulated within the hydrogel. Methods of preparing the hydrogels, and methods for the use o...
|
WO/2023/223714A1 |
Various two-residue-extended peptides can be produced by reacting a first amino acid or peptide represented by formula (1), a halogenating agent, a tertiary amine represented by formula (3), an amino acid N-carboxy anhydride (NCA) repres...
|
WO/2023/222006A1 |
The present invention relates to crystal forms A and B of a compound (HS378) of formula (I) and a preparation method therefor. The crystal forms A and B have a good physiochemical stability, a regular crystal habit, a good particle size ...
|
WO/2023/222558A1 |
A precursor compound for a therapeutic, FAP-targeted radiotracer comprises a chelator Ch for complexation of a radioisotope and one, two, three or four targeting vectors TV1, TV2, TV3, TV4, which independently of one another comprise a m...
|
WO/2023/217405A1 |
The present invention relates to photostabilized compositions comprising a water-soluble tyrosine- containing compound with a molecular weight of below 1kDa and at least one photosensitive component and a method for stabilizing photosens...
|
WO/2023/220549A1 |
The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
|
WO/2023/220722A2 |
PAK1 degraders and methods of use thereof are disclosed.
|
WO/2023/216533A1 |
The present invention relates to an indole alkaloid, and a preparation method therefor and the use thereof. Specifically disclosed in the present invention are a compound as shown in formula I and a preparation method therefor, and a pha...
|
WO/2023/214802A1 |
The present invention relates to a novel peptide comprising the sequence of the following general formula 1 or 2, and anti-inflammatory and regenerative uses thereof. [general formula 1] X-Gly-Ala-Tyr [general formula 2] Ala-X-Ser
|
WO/2023/212090A1 |
The invention provides an anti-aging peptide containing cosmetic. Also provided are methods of reducing the appearance of aging on the skin, especially skin around the eye. In accordance with an aspect of the present invention, there is ...
|
WO/2023/212322A2 |
Nanostructured chiral microparticles with bowtie shape having widely variable pitch, size, thickness and length are provided. The self-limited assembly of anisotropic building blocks makes possible high synthetic reproducibility, size mo...
|
WO/2023/211883A1 |
One aspect of the invention is any compound, or salt thereof, described herein. Another aspect is a method of treating a disease, disorder, or symptom thereof, in a subject, comprising administration to the subject of a compound, or salt...
|
WO/2023/209028A1 |
The invention relates to sulphonyl benzene derivatives, in particular to fluorinated sulphonyl benzene derivatives. It is provided a compound of formula (I) or general formula (IA) wherein X is fluorine; A is either O or NH; B is an amin...
|
WO/2023/205233A1 |
Disclosed are compounds comprising chemically modified gamma-hydroxybutyrate (GHB) having the structure of Formula I, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at...
|
WO/2023/205237A1 |
Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are...
|
WO/2023/204721A1 |
The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of kidney cancer. The invention also relates to an in vitro method for detec...
|
WO/2023/198195A1 |
Disclosed herein are compounds that are Toll-like receptor (TLR) agonist, conjugates comprising these compounds and cell targeting moiety, pharmaceutical compositions thereof, method of activating toll-like receptors 7 and/or 8 and metho...
|
WO/2023/197129A1 |
Compositions for oncolytic peptide therapeutics of cancer are provided. Methods of using such compositions containing the same are also described. Additionally, the oncolytic peptide can be used to inhibit tumor growth and decrease tumor...
|
WO/2023/198884A1 |
The present invention relates to ligand-drug-conjugates for the treatment of disease. In particular, the present invention relates to ligand-drug-conjugates comprising a linker system, which allows for improved delivery of a drug to a ta...
|
WO/2023/194418A1 |
Described herein are the mono hydrochloric acid salt, as well as the free zwitterion of the macrocyclic peptide antibiotic 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17- (1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4...
|
WO/2023/193085A1 |
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...
|
WO/2023/196765A1 |
Disclosed herein are intermediate preparations for the manufacture of glucagon and GLP-1 dual agonist compounds or pharmaceutically acceptable salts thereof. Also disclosed herein are processes for the manufacture of glucagon and GLP-1 d...
|
WO/2023/195577A1 |
Substances in the form of flexible disks to modulate mechanotransduction mediated by integrins were designed. Two main ideas for the design are as follows. First, the radius of the disk can be prescribed to specify the radius of mechanic...
|
WO/2023/192165A1 |
In various embodiments, the present disclosure pertains to compositions and methods for prevention or treatment of cancer, prevention, treatment or inhibition of viral or microbial infection or replication, or prevention, treatment or in...
|
WO/2023/185763A1 |
A peptidomimetic compound, and a preparation method, pharmaceutical composition and use therefor. Specifically, disclosed are a peptidomimetic compound represented by general formula (I), or a racemate, a cis-trans isomer, an enantiomer,...
|
WO/2023/188173A1 |
Provided is a component capable of effectively increasing intracerebral GABA. An agent for increasing intracerebral γ-aminobutyric acid (GABA), the agent containing a compound represented by formula I. (In the formula, R is a side chain...
|
WO/2023/191647A1 |
The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of intestinal cancer. The invention also relates to an in vitro method for d...
|